190 related articles for article (PubMed ID: 26303866)
1. Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach.
Nyberg F; Askling J; Berglind N; Franzén S; Ho M; Holmqvist M; Horne L; Lampl K; Michaud K; Pappas DA; Reed G; Symmons D; Tanaka E; Tran TN; Verstappen SM; Wesby-van Swaay E; Yamanaka H; Greenberg JD
Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1121-32. PubMed ID: 26303866
[TBL] [Abstract][Full Text] [Related]
2. Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease.
Michaud K; Berglind N; Franzén S; Frisell T; Garwood C; Greenberg JD; Ho M; Holmqvist M; Horne L; Inoue E; Nyberg F; Pappas DA; Reed G; Symmons D; Tanaka E; Tran TN; Verstappen SM; Wesby-van Swaay E; Yamanaka H; Askling J
Ann Rheum Dis; 2016 Oct; 75(10):1797-805. PubMed ID: 26857699
[TBL] [Abstract][Full Text] [Related]
3. Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries.
Verstappen SM; Askling J; Berglind N; Franzen S; Frisell T; Garwood C; Greenberg JD; Holmqvist M; Horne L; Lampl K; Michaud K; Nyberg F; Pappas DA; Reed G; Symmons DP; Tanaka E; Tran TN; Yamanaka H; Ho M
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1637-45. PubMed ID: 26201948
[TBL] [Abstract][Full Text] [Related]
4. How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries.
Askling J; Berglind N; Franzen S; Frisell T; Garwood C; Greenberg JD; Ho M; Holmqvist M; Horne L; Inoue E; Michaud K; Nyberg F; Pappas DA; Reed G; Tanaka E; Tran TN; Verstappen SM; Yamanaka H; Wesby-van Swaay E; Symmons D
Ann Rheum Dis; 2016 Oct; 75(10):1789-96. PubMed ID: 26621482
[TBL] [Abstract][Full Text] [Related]
5. Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme.
Yamanaka H; Askling J; Berglind N; Franzen S; Frisell T; Garwood C; Greenberg JD; Ho M; Holmqvist M; Novelli Horne L; Inoue E; Michaud K; Pappas DA; Reed G; Symmons D; Tanaka E; Tran TN; Verstappen SMM; Wesby-van Swaay E; Nyberg F
RMD Open; 2017; 3(2):e000498. PubMed ID: 29081988
[TBL] [Abstract][Full Text] [Related]
6. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment?
Tutuncu Z; Reed G; Kremer J; Kavanaugh A
Ann Rheum Dis; 2006 Sep; 65(9):1226-9. PubMed ID: 16414968
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries.
Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; McCroskery P; Baumgartner SW; Markenson JA
J Rheumatol; 2011 Jan; 38(1):21-8. PubMed ID: 20952478
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry.
Thorne C; Bensen WG; Choquette D; Chow A; Khraishi M; Atkins CJ; Kelsall JT; Lehman AJ; Shawi M; Khalil H; Nantel F; Rampakakis E; Sampalis JS; Otawa S
Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1142-51. PubMed ID: 24470077
[TBL] [Abstract][Full Text] [Related]
9. The status of fostamatinib in the treatment of rheumatoid arthritis.
Morales-Torres J
Expert Rev Clin Immunol; 2012 Sep; 8(7):609-15. PubMed ID: 23078058
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial.
Vanags D; Williams B; Johnson B; Hall S; Nash P; Taylor A; Weiss J; Feeney D
Lancet; 2006 Sep; 368(9538):855-63. PubMed ID: 16950363
[TBL] [Abstract][Full Text] [Related]
11. Kinase inhibitors for the treatment of rheumatoid arthritis.
Yazici Y; Steiger B
Bull NYU Hosp Jt Dis; 2012; 70(3):204-7. PubMed ID: 23259630
[TBL] [Abstract][Full Text] [Related]
12. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
13. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.
Anderson JJ; Bolognese JA; Felson DT
Arthritis Rheum; 2003 Nov; 48(11):3031-8. PubMed ID: 14613263
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
15. Clinical profile of 266 Filipino patients with rheumatoid arthritis included in the rheumatoid arthritis database and registry (RADAR) of the Philippine General Hospital.
Penserga EG; Natividad TA; Salido ES;
Int J Rheum Dis; 2015 May; 18(4):433-8. PubMed ID: 26010598
[TBL] [Abstract][Full Text] [Related]
16. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
Farahani P; Levine M; Gaebel K; Thabane L
Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
[TBL] [Abstract][Full Text] [Related]
17. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
18. Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research.
Curtis JR; Chen L; Bharat A; Delzell E; Greenberg JD; Harrold L; Kremer J; Setoguchi S; Solomon DH; Xie F; Yun H
Arthritis Care Res (Hoboken); 2014 Dec; 66(12):1790-8. PubMed ID: 24905637
[TBL] [Abstract][Full Text] [Related]
19. TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries.
Nasir A; Greenberg JD
Bull NYU Hosp Jt Dis; 2007; 65(3):178-81. PubMed ID: 17922666
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
